You are here

FDA Lifts Clinical Hold on Skeletal Targeted Radiotherapy

Seattle, WA, April 23, 2003 — NeoRx Corporation (Nasdaq: NERX) today announced that the US Food and Drug Administration (FDA) has lifted the clinical hold on the company’s Skeletal Targeted Radiotherapy (STR) product candidate for multiple myeloma, a cancer of the bone marrow.

The FDA’s decision follows NeoRx’s submission of data from a dosimetry study of STR, in which multiple myeloma patients were treated and detailed radiation dosimetry data were collected, as previously requested by the FDA. NeoRx continues to follow these patients for safety and efficacy results. Three-year survival data on the STR Phase I/II patients will be available by the end of 2003.

NeoRx also has submitted to the FDA a proposal for further clinical development of STR, and expects to submit a full Phase III study protocol before the end of the second quarter of this year for the FDA’s review.

“This is certainly good news for multiple myeloma patients and their physicians. STR is the only therapeutic in late-stage development that has demonstrated a significant complete response rate and offers the potential for prolonged progression-free survival and overall survival,” said William Bensinger, MD, Member, Fred Hutchinson Cancer Research Center (Seattle), Co-Principal Investigator and member of the Company’s Clinical Advisory Panel for STR.

“This decision is a major milestone for NeoRx. With the clinical hold lifted, and additional funds in hand from recent intellectual property agreements, we are at a turning point. We look forward to working with the FDA to finalize plans for the STR clinical program, and to enrolling multiple myeloma patients in further studies of this promising therapeutic,” said Jack L. Bowman, Executive Chairman and Chairman of the Board of Directors of NeoRx.

Recent Headlines

Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs